Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (GB:0HX7)
LSE:0HX7
Holding GB:0HX7?
Track your performance easily
0HX7 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $3.74
Previous Close$1.41
Volume6.00K
Average Volume (3M)3.30K
Market Cap
$121.95M
Enterprise Value-$82.98M
Total Cash (Recent Filing)$224.07M
Total Debt (Recent Filing)$19.13M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 06, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,400,960
10 Day Avg. Volume922
30 Day Avg. Volume3,300
Standard Deviation0.29
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.52
Price to Sales (P/S)0.67
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.46
Enterprise Value/Gross Profit-116.22
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$9.20Price Target Upside552.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Boardroom Changes as Leadership Transitions
PremiumCompany Announcements
Adicet Bio’s ADI-270 Gets FDA Fast Track for Cancer Therapy
PremiumCompany Announcements
Adicet Bio Advances with FDA Clearance and Upcoming Trial
PremiumCompany Announcements
Adicet Bio Shareholders Shape Future with Strategic VotesBulls Say, Bears Say
Bulls Say
Clinical DevelopmentsThe FDA cleared INDs for ADI-001 in systemic lupus erythematosus, systemic sclerosis, and ANCA-associated vasculitis.
Financial PerformanceThe company has a solid cash position of $224.1MM.
Innovative TherapiesAdicet’s ADI-270, a CD70-targeting CAR γδ T cell, demonstrated strong anti-tumor activity as well as a lower inflammatory profile.
Bears Say
Clinical TrialsRechallenged mice showed regrowth of tumor volume to injection levels, which could indicate a lack of long-term effective anti-tumor effects.
Financial PerformanceAdicet’s R&D expenses were higher than both the analyst's and consensus estimates.
Project DelaysThe company now plans to initiate its Phase 1 clinical study of ADI-001 for lupus nephritis, which is a slip in timing from the prior expectation of a trial initiation in June.
---
Options Prices
Currently, No data available
---
Ownership Overview
34.67% Insiders
7.59% Mutual Funds
53.64% Other Institutional Investors
4.09% Public Companies and
Individual Investors
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $1.06 and its highest was $3.74 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Nov 06, 2024 which is in 59 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Aug 13, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.364 by $0.034.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -$0.34.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,400,960 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.364. Following the earnings report the stock price went up 3.972%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is RA Capital Management. It holds Adicet Bio’s shares valued at 9M.
---
Adicet Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (552.48% Upside)
$9.20 (552.48% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.23%
12-Months-Change
Fundamentals
Return on Equity
-57.91%
Trailing 12-Months
Asset Growth
-3.17%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
0HX7 Stock 12 Month Forecast
Average Price Target
$9.20
▲(552.48% Upside)
Technical Analysis
Best Analysts Covering 0HX7
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-2.45%
reiterated a buy rating 26 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -2.45% per trade.
---